A Survey of Clinical Experience with Ciprofloxacin, a New Quinolone Antimicrobial

Publisher Website
Google Scholar
Abstract
Ciprofloxacin is a new quinolone antimicrobial agent with activity against a broad spectrum of gram‐negative and gram‐positive organisms, including Pseudomonas aeruginosa and methicillin‐resistant strains of staphylococci. The efficacy and safety results of 80 clinical studies of the oral form of ciprofloxacin are reported. Drug safety was assessed in 2236 courses in 2203 adult patients treated primarily in the Unites States. Data from 1676 courses were suitable for analysis of drug efficacy. The unit dose for most patients ranged from 250 mg to 750 mg (median, 500 mg), usually given every 12 hours. The duration of treatment ranged from 3 to 231 days (median, 10 days). Predominant among 1722 infections were those of the urinary tract (43%), skin structures (29%), and respiratory tract (19%); the remainder were bone and joint infections (5%), bacteremias (2%), and intra‐abdominal (1%), gastrointestinal (1%), and pelvic infections (.

This publication has 5 references indexed in Scilit: